Blood-based Shield by Guardant as a colorectal cancer screening option - will it satisfy the eCQM (CMS 130v14) measure

XMLWordPrintable

    • Type: EC eCQMs - Eligible Clinicians
    • Resolution: Answered
    • Priority: Moderate
    • Component/s: None
    • None
    • 4152976156
    • Commonspirit Health
    • Hide
      Thank you for your inquiry regarding CMS130v14 (2026 Performance Period). This measure is based on the guidelines from the U.S. Preventive Services Task Force (USPSTF), which does not recognize the colorectal cancer blood test as an acceptable option for meeting the measure's criteria. To meet the numerator requirements, applicable screenings include Fecal Occult Blood Test, Stool DNA with Fecal Immunochemical Test (FIT), Flexible Sigmoidoscopy, CT Colonography, or a colonoscopy. Clinically equivalent services may be mapped to the codes used in a measure's value sets to satisfy a value set requirement. If mapping is conducted, you should maintain documentation in case of a CMS audit. Please review the measure specification for further details about measure requirements: https://ecqi.healthit.gov/sites/default/files/ecqm/measures/CMS130-v14.0.000-QDM.html.
      Show
      Thank you for your inquiry regarding CMS130v14 (2026 Performance Period). This measure is based on the guidelines from the U.S. Preventive Services Task Force (USPSTF), which does not recognize the colorectal cancer blood test as an acceptable option for meeting the measure's criteria. To meet the numerator requirements, applicable screenings include Fecal Occult Blood Test, Stool DNA with Fecal Immunochemical Test (FIT), Flexible Sigmoidoscopy, CT Colonography, or a colonoscopy. Clinically equivalent services may be mapped to the codes used in a measure's value sets to satisfy a value set requirement. If mapping is conducted, you should maintain documentation in case of a CMS audit. Please review the measure specification for further details about measure requirements: https://ecqi.healthit.gov/sites/default/files/ecqm/measures/CMS130-v14.0.000-QDM.html .
    • CMS0130v14
    • Hide
      We have a provider office that wants to offer Shield by Guardant as a colorectal cancer screening option, but do not believe it will satisfy the eCQM (CMS 130v14) measurement requirements. While potentially more patients are screened, this will negatively impact the quality measure results.
      Show
      We have a provider office that wants to offer Shield by Guardant as a colorectal cancer screening option, but do not believe it will satisfy the eCQM (CMS 130v14) measurement requirements. While potentially more patients are screened, this will negatively impact the quality measure results.

      We have a provider office that wants to provide Shield by Guardant​, an FDA approved Colon Cancer Screening test​, as an alternative to colonoscopy, sigmoidoscopy, or fecal-based testing for colorectal cancer screening (Quality ID #113 (CBE 0034): Colorectal Cancer Screening. We have advised that this will not satisfy the ​eCQM (CMS 130v14) measurement specifications and presume it will not satisfy the 2026 Medicare CQM requirements. 
       
      Is it correct that the Shield by Guardant test will not satisfy the Quality ID #113 (CBE 0034): Colorectal Cancer Screening​ quality measure? 
       

            Assignee:
            AIR EC eCQM Team
            Reporter:
            Susan Merrill
            Votes:
            0 Vote for this issue
            Watchers:
            2 Start watching this issue

              Created:
              Updated:
              Resolved:
              Solution Posted On: